Tumour peptide antigen produced from human mdm2 proto-oncogene

A universal tumor-associated oligopeptide which is recognized as a peptide antigen by CD8-positive cytotoxic T lymphocytes (CTL) and produces a CTL-induced lysis and/or apoptosis of tumor or leukemia cells,

• characterized in that
• the oligopeptide (a) has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the human mdm2 (=hdm2) proto-oncoprotein, or an amino acid sequence derivable by amino acid substitution, deletion, insertion, addition, inversion and/or by chemical or physical modification of one or more amino acids thereof, which is a functional equivalent of the amino acid sequence LLGDLFGV, in that it (b) is an epitope for CD8-positive CTL, and in that (c) it is suitable for inducing a restricted immune response of CD8-positive CTL to human leukocyte antigen (HLA) of the molecular group “MHC class I”, allele variant “A2”, in particular subtype A2.1, agalnst tumor and leukemia cells.